Evidence map›Paper›PMID 28145427›Full record

ArticleEuropean journal of human genetics : EJHG2017

Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals.

Maya S Safarova, Eric W Klee, Linnea M Baudhuin, Erin M Winkler, Michelle L Kluge, Suzette J Bielinski, Janet E Olson, Iftikhar J Kullo

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Genomic medicine for kidney disease.Nature reviews. Nephrology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Maya S SafarovaDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Eric W KleeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Linnea M BaudhuinDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Erin M WinklerCenter for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Michelle L KlugeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Suzette J BielinskiDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Janet E OlsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Iftikhar J KulloDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US

Funding

Genomic Basis of Susceptibility to COVID-19 Infection and its ComplicationsU01HG006379 · NHGRI · MAYO CLINIC ROCHESTER · PI Richard R. Sharp · 2011 to 2026
$16.5M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
Pharmacogenomics and Risk of Cardiovascular DiseaseU19HL069757 · NHLBI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI KRAUSS, RONALD M · 2010 to 2014
$12.8M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
EMR Phenotypes and Community Engaged Genomic AssociationsU01HG004599 · NHGRI · MAYO CLINIC ROCHESTER · PI CHUTE, CHRISTOPHER G · 2007 to 2010
$3.7M
NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)U01GM097119 · NIGMS · WASHINGTON UNIVERSITY · PI MARDIS, ELAINE R · 2010 to 2014
$2.6M
Pharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1M
Pharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA138461NHGRI NIH HHS U01 HG004599NHGRI NIH HHS U01 HG005137NHGRI NIH HHS U01 HG006379NHLBI NIH HHS U19 HL069757NIA NIH HHS R01 AG034676NIGMS NIH HHS R01 GM028157NIGMS NIH HHS U01 GM097119NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Knowledge of variant pathogenicity is key to implementing genomic medicine. We describe variability between expert reviewers in assigning pathogenicity to sequence variants in LDLR, the causal gene in the majority of cases of familial hypercholesterolemia. LDLR was sequenced on the Illumina HiSeq platform (average read depth >200 × ) in 1013 Mayo Biobank participants recruited from 2012 to 2013. Variants with a minor allele frequency (MAF) <5% predicted to be functional or referenced in HGMD (Human Gene Mutation Database) or NCBI-ClinVar databases were reviewed. To assign pathogenicity, variant frequency in population data sets, computational predictions, reported observations and patient-level data including electronic health record-based post hoc phenotyping were leveraged. Of 178 LDLR variants passing quality control, 25 were selected for independent review using either an in-house protocol or a disease/gene-specific semi-quantitative framework based on the American College of Medical Genetics and Genomics-recommended lines of evidence. NCBI-ClinVar included interpretations for all queried variants with 74% (14/19) of variants with >1 submitter showing inconsistency in classification and 26% (5/19) appearing with conflicting clinical actionability. The discordance rate (one-step level of disagreement out of five classes in variant interpretation) between the reviewers was 40% (10/25). Two LDLR variants were independently deemed clinically actionable and returnable. Interpretation of LDLR variants was often discordant among ClinVar submitters and between expert reviewers. A quantitative approach based on strength of each predefined criterion in the context of specific genes and phenotypes may yield greater consistency between different reviewers.

Indexed as

AgedDatabases, GeneticElectronic Health RecordsFemaleGene FrequencyGenetic TestingHumansHyperlipoproteinemia Type IIIncidental FindingsMaleMiddle AgedObserver VariationPolymorphism, GeneticReceptors, LDLLDLR protein, humanReceptors, LDL

Identifiers

PMID28145427
PMCPMC5386413
OpenAlexW2585527171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.